Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Nov 01, 2007 (Vol. 27, No. 19)

Genome British Columbia

  • Abundance of well organized information on nanotechnology
  • None
Thinking about opportunities up north, eh? If so, Genome British Columbia may well be of interest for those with a molecular biological bent. The Overview page describes the $60-million investment program supporting genomics and (indirectly) agriculture, bioenergy, environment, fish and fisheries, forestry, and mining. The site’s rather schizophrenic nature (research/technology, society/ethics, applied genomics, and genomics education under one roof) works reasonably well, due to careful consideration of the needs of prospective customers. While the site itself leaves a bit to be desired in terms of labeling of information, the diversity of research interests and miscellaneous information (including a section on careers) makes the visit a worthwhile one. Definitely worth a look-see for anyone interested in genomics up north in Canada.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »